### Henry Ford Health

## Henry Ford Health Scholarly Commons

**Cardiology Articles** 

Cardiology/Cardiovascular Research

9-28-2021

## Cardiogenic Shock Management Should Be a Team Sport

Perwaiz M. Meraj

William O'Neill

Henry Ford Health, woneill1@hfhs.org

Follow this and additional works at: https://scholarlycommons.henryford.com/cardiology\_articles

### **Recommended Citation**

Meraj PM, and O'Neill WW. Cardiogenic Shock Management Should Be a Team Sport. J Am Coll Cardiol 2021; 78(13):1318-1320.

This Article is brought to you for free and open access by the Cardiology/Cardiovascular Research at Henry Ford Health Scholarly Commons. It has been accepted for inclusion in Cardiology Articles by an authorized administrator of Henry Ford Health Scholarly Commons.

### **EDITORIAL COMMENT**

# Cardiogenic Shock Management Should Be a Team Sport\*



Perwaiz M. Meraj, MD,<sup>a</sup> William W. O'Neill, MD<sup>b</sup>

he advent of percutaneous mechanical reperfusion therapy of acute myocardial infarction (AMI) in the 1980s (1) instilled the organization of medical care to be a series of sequential trade off of responsibilities from emergency department (ED) physician to catheterization laboratory interventional cardiologist to cardiac intensive care unit (CICU) attending. This same mechanism was incorporated into management of cardiogenic shock (CS). The ED physician identified shock, initiated vasopressor therapy, and transferred the patient to the catheterization laboratory where the interventional cardiologist treated the culprit vessel(s) and often inserted an intra-aortic balloon pump. The patient was transferred to the CICU and patients either survived or did not. For the last 30 years, the management was the same and the results, a 50% mortality rate, have been the same (2-4). The advent of mechanical circulatory support (MCS) devices, such as veno-arterial extracorporeal membrane oxygenator, Impella (Abiomed), Tandem Heart (LivaNova), and combinations of these MCS devices, has provided hope that survival may be improved with more effective support. To optimally use these devices, the process of care must evolve. No individual physician has the experience and background to perform complex PCI, large bore access, vascular cut downs, antegrade sheath limb perfusion, surgical ventricular assist device placement, and rapid determination of whether

\*Editorials published in the *Journal of the American College of Cardiology* reflect the views of the authors and do not necessarily represent the views of *JACC* or the American College of Cardiology.

From the <sup>a</sup>Department of Cardiology, Northwell Health, Manhasset, New York, USA; and the <sup>b</sup>Department of Cardiology, Henry Ford Health System, Detroit, Michigan, USA.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.

indicated. For this reason, creation of shock teams consisting of ED physicians, interventional cardiologists, cardiac ventricular assist device transplant surgeons, advanced heart failure cardiologists, cardiac intensivists, and palliative care specialists have been organized in many centers to optimize

and when escalation of care up to and including

emergency cardiac transplant is possible and

### SEE PAGE 1309

In this issue of the Journal, Papolos et al (9) discuss

cardiogenic shock care (5-8).

the management and outcomes of CS as it relates to CICU care with or without shock teams from the multicenter Critical Care Cardiology Trials Network. The authors are to be lauded for their focus on shock teams and postdevice CICU care (10), because these 2 areas are of such importance to further survival of patients in CS. From 2017 to 2019, over a 2-month period, the authors demonstrate that among the 1,242 CS admissions, 44% were at shock team centers, whereas 42% of sites had shock teams. Centers with shock teams were more likely to use invasive hemodynamics, pulmonary artery catheters (PACs), and advanced forms of MCS; however, overall, fewer patients received device therapy, mostly driven by decreased use of the intra-aortic balloon pump. Patient acuity was defined by the SOFA (Sequential Organ Failure Assessment) score, and all invasive hemodynamics were recorded. Centers where venoarterial extracorporeal membrane oxygenator is managed in the cardiothoracic ICU were not followed, which may lead to further confounding of the results, although both groups had similar numbers of such patients. Both AMI-CS and non-AMI-CS patients demonstrated improved mortality in CICU with shock teams compared with centers without shock teams. Inverse probability weighting was used to reduce confounders inherent in any observational analysis.

Meraj and O'Neill

Papolos et al (9) expanded on the previously reported evidence, which demonstrated improved survival from years 1 to 2 after the development of the shock team (8,11), by demonstrating the 28% lower adjusted odds of CICU mortality among CS patients in centers with shock teams. PAC utilization was significantly higher among centers with shock teams (60% vs 49%) and was placed much earlier in the patient's course (0.3 days vs 0.66 days). The combination of increased PAC use and more advanced MCS use appears to lead to the lower CICU mortality in both AMI and non-AMI CS. Although this is observational data, it supports the prior evidence to date where presence of a shock team can rapidly identify and treat patients in CS, prevent the multisystem organ failure that contributes to worse mortality, and decrease the need for renal replacement therapy and prolonged ventilation (7,8), and increased use of PAC leads to improved experience in interpreting, developing a treatment algorithm, and escalating care based on the data obtained (12,13).

An area not addressed in this paper is both escalation of care based on the invasive hemodynamics in the CICU and the protocols to prevent acute vascular/limb complications (ALI) that can arise from the use of MCS, especially in this population of patients. Performing routine peripheral angiography before cannula selection and early recognition of those at risk of developing ALI can play a key role in decreasing such events in these patients. Furthermore, keeping a low threshold for using percutaneous downstream perfusion cannula in high-risk patients can help

reducing events of distal ischemia; however, close monitoring of limb ischemia in the CICU is of utmost importance (14,15). Many procedural techniques and novel CICU models exist to mitigate the risk of ALI in CS patients with MCS (16,17). Finally, escalation of care and support is vital to the continued success of any shock team and center (18).

Although many critics will continue to discuss the lack of randomized controlled trials in the field of CS, this paper supports the process previously outlined of a multidisciplinary team-based approach improving survival. Establishing shock teams and CICUs that are based in centers dedicated to CS is the path to improved survival. Post-MCS care is of the utmost importance to escalate appropriately if patients are not improving and avoid ALI, which are typically fatal in these extremely ill patients. The continued support for shock teams is vital to the improvement in care models and survival while the randomized data on MCS use in CS continues to be developed.

### **FUNDING SUPPORT AND AUTHOR DISCLOSURES**

Dr Meraj has received research and grant funding from Abiomed Inc, Medtronic Inc, CSI, and Boston Scientific. Dr O'Neill has received consulting/speaker honoraria from Abiomed Inc, Boston Scientific, and Abbott Laboratories.

ADDRESS FOR CORRESPONDENCE: Dr Perwaiz M. Meraj, Department of Cardiology, Northwell Health, 300 Community Drive, Manhasset, New York 11030, USA. E-mail: PMeraj@northwell.edu. Twitter: @PerwaizMeraj, @BillONeillMD.

### REFERENCES

- **1.** Hartzler GO, Rutherford BD, McConahay DR, et al. Percutaneous transluminal coronary angioplasty with and without thrombolytic therapy for treatment of acute myocardial infarction. *Am Heart J.* 1983;106(5 Pt 1):965-973. https://doi.org/10.1016/0002-8703(83)90639-7
- **2.** Masoudi FA, Ponirakis A, de Lemos JA, et al. Trends in U.S. Cardiovascular Care: 2016 report from 4 ACC National Cardiovascular Data Registries. *J Am Coll Cardiol*. 2017;69(11):1427-1450. https://doi.org/10.1016/j.jacc.2016.12.005
- **3.** Miller L. Cardiogenic shock in acute myocardial infarction: the era of mechanical support. *J Am Coll Cardiol*. 2016;67(16):1881-1884. https://doi.org/10.1016/j.jacc.2015.12.074
- **4.** Truesdell AG, Tehrani B, Singh R, et al. 'Combat' approach to cardiogenic shock. *Interv Cardiol*. 2018;13(2):81-86. https://doi.org/10.15420/icr. 2017:35:3
- **5.** Tehrani B, Truesdell A, Singh R, Murphy C, Saulino P. Implementation of a cardiogenic shock team and clinical outcomes (INOVA-SHOCK Registry): observational and retrospective study. *JMIR*

- Res Protoc. 2018;7(6):e160. https://doi.org/10. 2196/resprot.9761
- **6.** Tehrani BN, Rosner CM, Batchelor WB. Evolving paradigms in cardiogenic shock care. *Aging (Albany NY)*. 2019;11(13):4303–4304. https://doi.org/10.18632/aging.102075
- **7.** Tehrani BN, Truesdell AG, Sherwood MW, et al. Standardized team-based care for cardiogenic shock. *J Am Coll Cardiol*. 2019;73(13):1659-1669. https://doi.org/10.1016/j.jacc.2018.12.084
- **8.** Basir MB, Kapur NK, Patel K, et al. Improved outcomes associated with the use of shock protocols: updates from the national cardiogenic shock initiative. *Catheter Cardiovasc Interv.* 2019;93(7):1173-1183. https://doi.org/10.1002/ccd.28307
- **9.** Papolos AI, Kenigsberg BB, Berg DD, et al. Management and outcomes of cardiogenic shock in cardiac ICUs with versus without shock teams. *J Am Coll Cardiol*. 2021;78:1309–1317.
- **10.** Na SJ, Park TK, Lee GY, et al. Impact of a cardiac intensivist on mortality in patients with

- cardiogenic shock. *Int J Cardiol*. 2017;244:220-225. https://doi.org/10.1016/j.ijcard.2017.06.082
- **11.** Tehrani BN, Truesdell AG, Psotka MA, et al. A standardized and comprehensive approach to the management of cardiogenic shock. *J Am Coll Cardiol HF*. 2020;8(11):879-891. https://doi.org/10.1016/j.jchf.2020.09.005
- **12.** Garan AR, Kanwar M, Thayer KL, et al. Complete hemodynamic profiling with pulmonary artery catheters in cardiogenic shock is associated with lower in-hospital mortality. *J Am Coll Cardiol HF*. 2020;8(11):903–913. https://doi.org/10.1016/j.jchf.2020.08.012
- **13.** O'Neill WW, Grines C, Schreiber T, et al. Analysis of outcomes for 15,259 US patients with acute myocardial infarction cardiogenic shock (AMICS) supported with the Impella device. *Am Heart J.* 2018;202:33–38. https://doi.org/10.1016/j.ahj. 2018.03.024
- **14.** Thiele H, Lauer B, Hambrecht R, Boudriot E, Cohen HA, Schuler G. Reversal of cardiogenic shock by percutaneous left atrial-to-femoral arterial bypass assistance. *Circulation*.

#### 2001;104(24):2917-2922. https://doi.org/10.1161/ hc4901.100361

- 15. Thiele H, Sick P, Boudriot E, et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J. 2005;26(13):1276-1283. https://doi.org/ 10.1093/eurheartj/ehi161
- 16. Beck JR, Holt DW, Chan C, et al. Discussion: can upper extremity (deltoid) near infrared spec-
- troscopy be used to assess cerebral tissue bed saturation on femorally cannulated veno-arterial extracorporeal membrane oxygenation patients? Perfusion. 2021;36(2):190-199. https://doi.org/ 10.1177/0267659120906769
- 17. Patton-Rivera K, Beck J, Fung K, et al. Using nearinfrared reflectance spectroscopy (NIRS) to assess distal-limb perfusion on venoarterial (V-A) extracorporeal membrane oxygenation (ECMO) patients with femoral cannulation. Perfusion. 2018;33(8):618-623. https://doi.org/10.1177/0267659118777670
- 18. Bertoldi LF, Delmas C, Hunziker P, Pappalardo F. Escalation and de-escalation of mechanical circulatory support in cardiogenic shock. Eur Heart J Suppl. 2021;23(Suppl A):A35-A40. https://doi.org/10.1093/eurheartj/suab007

KEY WORDS cardiac intensive care unit, cardiogenic shock, mechanical circulatory support, pulmonary artery catheter, shock team